Triple Drug Combination for Type 1 Diabetes Beta-Cell Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 1 diabetes, such as lifelong insulin injections, often lead to complications like hypoglycemia and are not curative, with a need for new methods that can preserve or regenerate β-cells to reduce insulin dependency.
Innovation Solution
A combination therapy of a dipeptidase-4 inhibitor (DPP-4), a proton pump inhibitor (PPI), and gamma-aminobutyric acid (GABA) or its receptor agonist, administered orally, which works to regenerate β-cells and reduce insulin requirements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifelong insulin injections are administered to treat type 1 diabetes, then blood glucose control is maintained, but the patient develops complications such as hypoglycemia and becomes permanently dependent on insulin
Solution Approach 1:
The patent uses a combination of three substances (DPP-4 inhibitor, PPI, and GABA or GABA receptor agonist) as intermediary agents that mediate between the autoimmune destruction of beta-cells and the need for insulin. This combination therapy acts as a bridge to preserve remaining beta-cell function and reduce autoimmune attack, thereby reducing insulin dependency while maintaining glucose control.
Solution Approach 2:
The patent changes the therapeutic parameters by introducing a triple combination therapy that targets multiple pathways simultaneously: DPP-4 inhibition to preserve incretin activity, PPI to reduce gastric acid and potentially protect beta-cells, and GABA to modulate neuronal regulation of insulin secretion. This multi-parameter approach allows for reduced insulin dosing while maintaining glycemic control.
2Adaptability or versatility
If new drugs are developed to preserve or regenerate beta-cells, then insulin dependency can be reduced, but the treatment complexity and development cost increase
Solution Approach 1:
The patent merges three different therapeutic agents into a single combination regimen that targets multiple aspects of beta-cell protection and regeneration. By combining DPP-4 inhibitor, PPI, and GABA-based therapy, the patent creates a synergistic effect that addresses both the autoimmune destruction and the functional preservation of beta-cells, thereby reducing insulin dependency through a coordinated multi-target approach.
3Reliability
If proton pump inhibitors are administered to patients with type 1 diabetes, then beta-cell function may be preserved, but the long-term effects and interactions with other medications are not fully understood
Solution Approach 1:
The patent incorporates monitoring and assessment mechanisms to track beta-cell function, insulin requirements, and potential side effects over time. This feedback approach allows for adjustment of the combination therapy based on individual patient responses, thereby gathering real-world safety and efficacy data while optimizing treatment outcomes.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention applies to the field of medicine, namely to endocrinology, and can be used to treat type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase-4 (DPP-4) inhibitor, a proton pump inhibitor (PPI), and gamma-aminobutyric acid or a gamma-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of the β-cells of the pancreas, presented by a dramatic reduction of insulin requirements up to a total insulin discontinuation in some persons and is intended for the treatment of type 1 diabetes mellitus.